Cargando…

Incidence of Viral Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir

IMPORTANCE: Some patients treated with nirmatrelvir-ritonavir have experienced rebound of COVID-19 infections and symptoms; however, data are scarce on whether viral rebound also occurs in patients with COVID-19 receiving or not receiving molnupiravir. OBJECTIVE: To examine the incidence of viral re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wong, Grace Lai-Hung, Yip, Terry Cheuk-Fung, Lai, Mandy Sze-Man, Wong, Vincent Wai-Sun, Hui, David Shu-Cheong, Lui, Grace Chung-Yan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856258/ https://www.ncbi.nlm.nih.gov/pubmed/36472873 http://dx.doi.org/10.1001/jamanetworkopen.2022.45086

Ejemplares similares

Clinical Outcomes Following Treatment for COVID-19 With Nirmatrelvir/Ritonavir and Molnupiravir Among Patients Living in Nursing Homes
por: Ma, Bosco Hon-Ming, et al.
Publicado: (2023)

Minimal Risk of Drug-Induced Liver Injury With Molnupiravir and Ritonavir-Boosted Nirmatrelvir
por: Wong, Grace Lai-Hung, et al.
Publicado: (2023)

Three COVID-19 medications-remdesivir, molnupiravir and ritonavir-boosted nirmatrelvir-and serial liver biochemistries in 22, 456 subjects
por: Wong, Grace Lai-Hung, et al.
Publicado: (2022)

Association of Molnupiravir and Nirmatrelvir-Ritonavir with reduced mortality and sepsis in hospitalized omicron patients: a territory-wide study
por: Wai, Abraham Ka-chung, et al.
Publicado: (2023)

Nirmatrelvir–Ritonavir and Viral Load Rebound in Covid-19
por: Anderson, Annaliesa S., et al.
Publicado: (2022)

Molnupiravir and nirmatrelvir–ritonavir reduce mortality risk during post-acute COVID-19 phase()
por: Wan, Eric Yuk Fai, et al.
Publicado: (2023)

Clinical characteristics of COVID-19 rebound after nirmatrelvir-ritonavir or molnupiravir therapy: A prospective cohort study
por: Han, Jaijun, et al.
Publicado: (2023)

Effectiveness of molnupiravir vs nirmatrelvir-ritonavir in non-hospitalised and hospitalised patients with COVID-19: a target trial emulation study
por: Wan, Eric Yuk Fai, et al.
Publicado: (2023)

New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19
por: Atmar, Robert L., et al.
Publicado: (2022)

Molnupiravir and Nirmatrelvir/Ritonavir: Tolerability, Safety, and Adherence in a Retrospective Cohort Study
por: Mazzitelli, Maria, et al.
Publicado: (2023)

Association of Molnupiravir and Nirmatrelvir-Ritonavir with preventable mortality, hospital admissions and related avoidable healthcare system cost among high-risk patients with mild to moderate COVID-19
por: Wai, Abraham Ka-Chung, et al.
Publicado: (2022)

COVID-19 “Rebound” associated with nirmatrelvir/ritonavir pre-hospital therapy
por: Coulson, J.M., et al.
Publicado: (2022)

SARS-CoV-2 virologic rebound with nirmatrelvir-ritonavir therapy
por: Edelstein, Gregory E., et al.
Publicado: (2023)

Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong
por: Lui, David T. W., et al.
Publicado: (2023)

Nirmatrelvir or Molnupiravir Use and Severe Outcomes From Omicron Infections
por: Lin, Dan-Yu, et al.
Publicado: (2023)

Virological and clinical rebounds of COVID-19 soon after nirmatrelvir/ritonavir discontinuation
por: Antonelli, Guido, et al.
Publicado: (2022)

Rebound of SARS-CoV-2 Infection after Nirmatrelvir–Ritonavir Treatment
por: Charness, Michael E., et al.
Publicado: (2022)

547. Molnupiravir and Nirmatrelvir/Ritonavir Effectiveness in Reducing the Risk for COVID-19 Disease Progression and Death
por: Paraskevis, Dimitrios, et al.
Publicado: (2023)

Moving toward hepatitis B virus functional cure - the impact of on-treatment kinetics of serum viral markers
por: Liang, Lilian Yan, et al.
Publicado: (2023)

Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study
por: Gentile, Ivan, et al.
Publicado: (2022)

Comparing molnupiravir and nirmatrelvir/ritonavir efficacy and the effects on SARS-CoV-2 transmission in animal models
por: Cox, Robert M., et al.
Publicado: (2023)

514. Nirmatrelvir/ritonavir or Molnupiravir for Treatment of Non-hospitalized Patients with COVID-19 at Risk of Disease Progression
por: Butt, Adeel A, et al.
Publicado: (2023)

Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact
por: Yip, Terry Cheuk-Fung, et al.
Publicado: (2021)

Alanine Aminotransferase Level: The Road to Normal in 2021
por: Yip, Terry Cheuk‐Fung, et al.
Publicado: (2021)

Real-World Study on Effectiveness of Molnupiravir and Nirmatrelvir–Ritonavir in Unvaccinated Patients with Chronic Respiratory Diseases with Confirmed SARS-CoV-2 Infection Managed in Out-Patient Setting
por: Kwok, Wang Chun, et al.
Publicado: (2023)

COVID-19 redux: clinical, virologic, and immunologic evaluation of clinical rebound after nirmatrelvir/ritonavir
por: Epling, Brian P., et al.
Publicado: (2022)

Acute pulmonary emboli following rebound phenomenon after Nirmatrelvir/Ritonavir treatment for COVID-19
por: Birabaharan, Morgan, et al.
Publicado: (2022)

Acute pulmonary emboli following rebound phenomenon after Nirmatrelvir/Ritonavir treatment for COVID-19
por: Zheng, Qian, et al.
Publicado: (2023)

Nirmatrelvir and Molnupiravir and Post–COVID-19 Condition in Older Patients
por: Fung, Kin Wah, et al.
Publicado: (2023)

SARS-CoV-2 Viral Persistence Based on Cycle Threshold Value and Liver Injury in Patients With COVID-19
por: Wong, Grace Lai-Hung, et al.
Publicado: (2021)

Effectiveness and Adverse Events of Nirmatrelvir/Ritonavir Versus Molnupiravir for COVID-19 in Outpatient Setting: Multicenter Prospective Observational Study
por: Park, Jin Ju, et al.
Publicado: (2023)

Oral Molnupiravir and Nirmatrelvir/Ritonavir for the Treatment of COVID-19: A Literature Review with a Focus on Real-World Evidence
por: Karniadakis, Ioannis, et al.
Publicado: (2023)

Secondary prevention for hepatocellular carcinoma in patients with chronic hepatitis B: are all the nucleos(t)ide analogues the same?
por: Yip, Terry Cheuk-Fung, et al.
Publicado: (2020)

Nirmatrelvir-ritonavir for COVID-19
por: McDonald, Emily G, et al.
Publicado: (2022)

Nirmatrelvir and ritonavir for COVID-19
Publicado: (2022)

Does Nirmatrelvir/Ritonavir Influence the Immune Response against SARS-CoV-2, Independently from Rebound?
por: Panza, Francesca, et al.
Publicado: (2023)

Immunologic characterization of a patient with clinical and virologic rebound upon Nirmatrelvir/Ritonavir treatment: the unfortunate epilogue of COVID-19
por: Marchetti, Giulia, et al.
Publicado: (2023)

Real-World Experience of the Comparative Effectiveness and Safety of Molnupiravir and Nirmatrelvir/Ritonavir in High-Risk Patients with COVID-19 in a Community Setting
por: Mutoh, Yoshikazu, et al.
Publicado: (2023)

Comparative Evaluation of GS-441524, Teriflunomide, Ruxolitinib, Molnupiravir, Ritonavir, and Nirmatrelvir for In Vitro Antiviral Activity against Feline Infectious Peritonitis Virus
por: Barua, Subarna, et al.
Publicado: (2023)

528. Matched Retrospective Study, Comparing Molnupiravir to Nirmatrelvir-Ritonavir (Paxlovid) in the Treatment of Mild-Moderate COVID-19 in Immunocompromised Cancer Patients
por: Haddad, Andrea, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rdmss9ei6b9t2c1mkdsbn7i71k